Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Show more

Location: 245 First Street, Cambridge, MA, 02142, United States | Website: https://www.akebia.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare

Market Cap

374.2M

52 Wk Range

$1.30 - $4.08

Previous Close

$1.45

Open

$1.47

Volume

2,307,840

Day Range

$1.40 - $1.48

Enterprise Value

406.7M

Cash

166.4M

Avg Qtr Burn

N/A

Insider Ownership

3.56%

Institutional Own.

49.88%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Auryxia (ferric citrate) Details Chronic kidney disease, Anemia, Kidney disease, Hyperphosphatemia	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vafseo™ (Vadadustat) Details Chronic kidney disease, Anemia, Kidney disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Praliciguat (SGC Stimulator) Details Focal Segmental Glomerulosclerosis (FSGS)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AKB-097 (Complement Inhibitor) Details IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AKB-097 (Complement Inhibitor) Details Complement-Mediated Rare Kidney Diseases (IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AKB-9090 (HIF-PH Inhibitor) Details Acute Kidney Injury Associated With Cardiac Surgery	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AKB-9090 (HIF-PH Inhibitor) Details Acute Kidney Injury Associated With Cardiac Surgery	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vafseo™ (Vadadustat) Details Chronic kidney disease, Anemia, Kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.